RxDoctor Payments DataLook up a doctor →

Michael Mullins, MD

Pulmonary Disease · Savannah, GANPI 1285602854

Payments from drug & device makers

$131,516in general payments, 2019–2025

Across 855 payments — averaging $153.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$45K
  • Ethicon Endo-surgery Inc.$38K
  • Medical Device Business Services, Inc.$36K
  • GSK$3K
  • AstraZeneca$2K
  • Insmed, Inc.$990
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$103,59779%
  • Travel & lodging$12,0529%
  • Food & beverage$15,56112%
  • Education$3070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,516 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$451,245
Medicare patients
1,514
Services billed
7,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate32$413,890
Trelegy ElliptaFluticasone/Umeclidin/Vilanter377$289,816
Prolastin CAlpha-1-Proteinase Inhibitor12$168,598
Dupixent PenDupilumab13$48,103
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$41,615
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$26,107
Breo ElliptaFluticasone/Vilanterol46$25,316
EliquisApixaban39$25,004
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$17,863
SymbicortBudesonide/Formoterol Fumarate28$8,768
Combivent RespimatIpratropium/Albuterol Sulfate12$6,870
Arnuity ElliptaFluticasone Furoate27$6,705
Albuterol Sulfate HfaAlbuterol Sulfate252$6,450
Advair HfaFluticasone Propion/Salmeterol17$5,425
Levofloxacin34$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat$768$438,62378 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$3,117$347,944501 claims
Grifols USA, LLCProlastin C$335$168,59812 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,480$50,38377 claims
PfizerEliquis$47$25,00439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →